The Journey of Ciprofloxacin

Ciprofloxacin is a fluoroquinolone with oral bioavailability of
70-80%, among the highest in its class. Absorption occurs primarily in the small intestine via
passive diffusion of the zwitterionic form; the molecule carries both a basic piperazine nitrogen
(pKa 6.1) and a carboxylic acid (pKa 8.7). Food modestly delays but does not substantially
reduce overall absorption. Divalent and trivalent cations — calcium (dairy), magnesium, aluminum
(antacids), zinc, and iron — form insoluble chelates with the 3-carboxyl/4-keto group of
ciprofloxacin, reducing bioavailability by up to 90%. This interaction requires that ciprofloxacin
be taken 2 hours before or 6 hours after cation-containing products. Intravenous ciprofloxacin
achieves peak concentrations roughly twice those of the equivalent oral dose but clinical outcomes
for many infections are equivalent, supporting oral therapy in compliant patients.

Ciprofloxacin distributes exceptionally widely. Its volume of
distribution is 2-3 L/kg, indicating extensive tissue penetration beyond the vascular
compartment. Plasma protein binding is moderate at 20-40%. High concentrations are achieved
in lung tissue (3-5 times plasma), bile (10-20 times plasma), prostate (2 times plasma), bone,
sinus secretions, skin, and phagocytes. Intracellular concentrations inside macrophages and
polymorphonuclear leukocytes significantly exceed extracellular levels — a key advantage for
treating intracellular pathogens such as Legionella, Salmonella, and Mycobacteria. CSF
penetration is limited (6-10% of plasma) in the absence of meningeal inflammation. Urinary
concentrations are very high (100-200 times plasma) as ciprofloxacin concentrates in the
collecting system, explaining its efficacy in urinary tract infections at relatively low doses.

Ciprofloxacin targets two essential bacterial topoisomerases:
DNA gyrase (topoisomerase II, composed of GyrA and GyrB subunits) and topoisomerase IV
(ParC and ParE subunits). Both enzymes are essential for DNA replication: gyrase introduces
negative supercoils ahead of the replication fork to relieve torsional stress, and topoisomerase
IV decatenates daughter chromosomes after replication. The enzymes function by creating a
transient double-strand break, passing another DNA segment through, and religating. Ciprofloxacin
intercalates at the enzyme-DNA interface, stabilizing the covalent cleavage complex and
preventing religation. The resulting stalled complexes become lethal when encountered by the
replication fork — each collision converts a reversible cleavage complex into an irreversible
double-strand break, triggering the bacterial SOS response and RecA-mediated DNA repair pathways
that paradoxically contribute to cell death. Gram-negative organisms (Enterobacteriaceae,
Pseudomonas) are primarily killed through gyrase inhibition; gram-positive cocci are more
sensitive to topoisomerase IV inhibition.

Ciprofloxacin undergoes partial hepatic metabolism, with
approximately 15-20% converted to four metabolites: desethyleneciprofloxacin, sulfociprofloxacin,
oxociprofloxacin, and formylciprofloxacin. Each retains some antibacterial activity (25-50% of
parent). The responsible enzymes include CYP1A2 and CYP3A4. Ciprofloxacin is a potent inhibitor
of CYP1A2, with clinically significant consequences: co-administration with theophylline or
caffeine (both CYP1A2 substrates) can increase their plasma levels 2-4-fold, requiring dose
reduction and monitoring. Clozapine, tizanidine, and duloxetine (CYP1A2 substrates) are also
at risk. The magnitude of CYP1A2 inhibition is dose-dependent and most pronounced with high
systemic exposure.

Ciprofloxacin is eliminated by both renal and non-renal routes.
Approximately 40-50% of an oral dose is recovered unchanged in urine, reflecting combined
glomerular filtration and tubular secretion via OAT1 and OAT3. Non-renal elimination includes
biliary excretion (15-20% as parent drug in feces) and intestinal secretion. The elimination
half-life is 3.5-5 hours in healthy adults. In severe renal impairment (creatinine clearance
< 30 mL/min), half-life extends to 8-12 hours, warranting dose reduction. Hemodialysis removes
only a small fraction (10-15%) due to the large volume of distribution. Peritoneal dialysis
removes minimal ciprofloxacin.

Ciprofloxacin remains the drug of choice for uncomplicated urinary
tract infections caused by susceptible gram-negative organisms, typhoid fever, inhalational
anthrax prophylaxis, and some sexually transmitted infections. Resistance emergence via GyrA
point mutations (Ser83Leu, Asp87Asn) and efflux pump overexpression (MexAB-OprM in Pseudomonas)
has substantially eroded its empiric utility in many settings. Fluoroquinolone-associated
disability and neuropathy syndrome (FQAD) — comprising tendinopathy, peripheral neuropathy,
aortic aneurysm risk, and psychiatric effects — has led regulatory agencies to restrict
use for uncomplicated infections. QT prolongation risk mandates caution with other QT-prolonging
agents and in hypokalemia.